相关实验视频

Updated: Jan 10, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

低氧激活生物降解基共价有机框架用于通过多种调节途径进行癌症铁灭菌疗法

Yulong Liu¹, Jun Wang², Ziqi Wang^2,3

¹General Surgery Department, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.

ACS applied materials & interfaces

|November 24, 2025

概括

这项研究引入了一种新材料 (BFCOF),通过降低谷氨 (GSH) 和缓解瘤缺氧,增强铁灭癌症治疗. 这种方法将铁与光热疗法进行协同作用,以提高抗瘤疗效和生物安全性.

科学领域:

生物医学工程生物医学工程
材料科学材料科学材料科学
在瘤学瘤学.

背景情况:

铁灭症治疗受到高谷氨 (GSH) 水平和瘤缺氧的限制.
开发新的策略来克服这些局限性对于有效的癌症治疗至关重要.

研究的目的:

制造一种由低氧激活的,可生物降解的基于氨酸的共价有机框架 (HPCOF),载有l-布氨酸硫胺 (BSO) 和Fe3+,经过氨酸 (HA) 修改,称为BFCOF.
研究BFCOF的多式疗法潜力,用于增强铁和协同癌症治疗.

主要方法:

通过将BSO和Fe3+加载到HPCOF上制造BFCOF,然后进行HA修改.
评估BFCOF产生活性氧物种 (ROS),诱导脂质过氧化 (LPO) 和耗尽细胞内GSH的能力.
评估ferroptosis诱导,光热疗法,低氧缓解和BFCOF的生物安全性在体外和体内.

主要成果:

BFCOF有效地产生单片氧 (1O2) 和基 (·OH),促进LPO和铁亡.
BSO负载和Fe3+/Fe2+循环协同耗尽了GSH,使GPX4无活化并增强了铁亡.
通过产生O2,BFCOF减轻了瘤缺氧,并且由于生物降解性,显示出良好的生物安全性.

结论:

在铁灭症治疗中,BFCOF代表了克服GSH过度表达和缺氧的新策略.
由BFCOF调解的铁和光热疗法的协同组合提供了更好的癌症治疗疗效.
BFCOF证明了先进的多模式癌症治疗的潜力,具有出色的生物安全性.

关键词:

这是一种GSH耗尽的过程.共价有机框架是共价有机框架.铁性化 (ferroptosis) 是一种协同效应疗法是一种协同效应疗法.调节瘤微环境的调节

更多相关视频

Author Spotlight: Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry

Author Spotlight: Porphyrin-Modified Beads for Use as Compensation Controls in Flow Cytometry

Published on: March 24, 2023

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles

One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles

Published on: September 17, 2013

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...